Increased plasma immunoreactive neuropeptide Y concentrations in phaeochromocytoma and chronic renal failure.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Hypertension

• Publication date

  1987-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004872-198712000-00020PMID 3429875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic pressor action of neuropeptide Y and norepinephrine in conscious rats.

  1986cited by this paper
• Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action.

  1985cited by this paper
• Neuropeptide Y in bovine adrenal glands: distribution and characterization.

  1985cited by this paper
• Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue.

  1984cited by this paper
• Neuropeptide Y and noradrenaline interaction in peripheral cardiovascular control.

  1984cited by this paper
• Demonstration of a neuropeptide Y-like immunoreactivity in human phaeochromocytoma extracts.

  1984cited by this paper
• Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine.

  1984cited by this paper
• Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers.

  1984cited by this paper
• Neuropeptide Y: regional distribution chromatographic characterization and immunohistochemical demonstration in post-mortem human brain.

  1984cited by this paper
• High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man.

  1983cited by this paper
• Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas.

  1983cited by this paper
• Neuropeptide tyrosine (NPY)--a major cardiac neuropeptide.

  1983cited by this paper
• Neuropeptide Y distribution in human brain

  1983cited by this paper
• Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat.

  1983cited by this paper
• Mechanism of elevated serum pancreatic polypeptide concentrations in chronic renal failure.

  1982cited by this paper
• Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

  1982cited by this paper
• Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide

  1982cited by this paper
• Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade.

  1982cited by this paper
• Neuropeptide Y: complete amino acid sequence of the brain peptide.

  1982cited by this paper
• Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism.

  1980cited by this paper
• Serum levels of human pancreatic polypeptide in renal disease.

  1977cited by this paper
• Renal handling of low molecular weight proteins.

  1975cited by this paper
• Hyperglucagonemia of renal failure.

  1974cited by this paper
• Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity

  1962cited by this paper

• Neuropeptide Y in cancer—biological functions and potential clinical implications

  2025cites this paper
• Comparison of Myocardial Perfusion during Hemodialysis and Hemodiafiltration

  2014cites this paper
• Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes.

  2011cites this paper
• The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer.

  2011cites this paper
• Expression of peptide YY in human brain and pituitary tissues.

  2008cites this paper
• Vitamin C

  2007cites this paper
• Elevated Plasma Immunoreactive Concentrations and Its Increased Patients with Advanced Diabetic Neuropeptide Y Urinary Excretion in Nephropathy

  2006cites this paper
• Neuropeptide Y and sympathetic control of vascular tone in hypertension.

  2006cites this paper
• Neuropeptide Y and the Kidney

  2004cites this paper
• Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors

  2004cites this paper
• PP, PYY and NPY: Synthesis, Storage, Release and Degradation

  2004cites this paper
• Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.

  2003cites this paper
• Adrenomedulin from a Pheochromocytoma to the Eye : Implications of the Adrenomedulin Research for Endocrinology in the 21 st Century

  2003influential citation
• Adrenomedullin from a pheochromocytoma to the eye: implications of the adrenomedullin research for endocrinology in the 21st century.

  2001cites this paper
• Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy.

  1999cites this paper
• Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats

  1998cites this paper
• Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure.

  1997cites this paper
• SR 120819A or the first Generation of orally active Y1-receptor antagonists

  1997cites this paper
• Urinary immunoreactive brain natriuretic peptide in patients with renal disease.

  1996cites this paper
• A population study of plasma neuropeptide Y: correlations with components of the metabolic syndrome.

  1996cites this paper
• Ambulatory 24-hour blood pressure and peptide balance in hemodialysis patients.

  1995cites this paper
• Plasma neuropeptide Y and catecholamines in women and men with essential hypertension.

  1995cites this paper
• Neuropeptide Y: a possible role in hypertension?

  1995cites this paper
• Laboratory diagnosis in hypertension

  1994cites this paper
• Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure.

  1994cites this paper
• Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age‐adjusted reference interval

  1994cites this paper
• Effects of Clonidine on Plasma Catecholamines and Neuropeptide Y in Hypertensive Patients at Rest and During Stress

  1993cites this paper
• Origin and Actions of Neuropeptide Y in the Cardiovascular System

  1993cites this paper
• Chapter 16 – Neuropeptides in Human Cardiovascular Regulation

  1993cites this paper
• An ACTH-secreting bronchial carcinoid: presence of corticotropin-releasing hormone, neuropeptide Y and endothelin-1 in the tumor tissue.

  1993cites this paper
• Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power of measuring plasma NPY using antisera with different specificities.

  1993cites this paper
• Plasma levels of vasoactive regulatory peptides in patients receiving regular hemodialysis treatment.

  1992cites this paper
• Platelet neuropeptide Y in spontaneously hypertensive rats

  1992cites this paper
• Plasma concentration of neuropeptide Y in patients with adrenal hypertension.

  1992cites this paper
• Therapy of Hypertension in End-Stage Renal Disease

  1992cites this paper
• Neuropeptide Y as a plasma marker for phaeochromocytoma, ganglioneuroblastoma and neuroblastoma.

  1992cites this paper
• NEUROENDOCRINOLOGY OF CHRONIC RENAL FAILURE AND RENAL TRANSPLANTATION

  1991cites this paper
• Age‐Dependent Hyperresponsiveness of Spontaneously Hypertensive Rats to the Pressor Effects of Intravenous Neuropeptide Y (NPY): Role of Mode of Peptide Administration and Plasma NPY‐Like Immunoreactivity

  1991cites this paper
• Alterations in circulating levels and cardiovascular tissue content of neuropeptide Y‐like immunoreactivity during the development of deoxycorticosterone acetate‐salt hypertension in the rat

  1991cites this paper
• Adrenal and retroperitoneal mixed neuroendocrine-neural tumors

  1991cites this paper
• Adreno-medullary hypertension: a review of syndromes, pathophysiology, diagnosis, and treatment.

  1991cites this paper
• Release of neuropeptide Y from pheochromocytomas.

  1990cites this paper
• Clinical Evaluation of Neuropeptide Y as a Plasma Marker of Tumors Derived from Neural Crest

  1990cites this paper
• Neuropeptide Y: An overview

  1990cites this paper
• Radioimmunoassay for plasma neuropeptide-Y in physiological and physiopathological states and response to sympathetic activation.

  1990cites this paper
• Functional relationships between platelet alpha 2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states.

  1990cites this paper
• Regulatory Peptides in Renal Failure: Effects and Possible Pathophysiological Role

  1990cites this paper
• Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR).

  1989cites this paper
• Radioimmunoassay of neuropeptide Y (NPY) in biological fluids. Circulating NPY levels depend on renal function.

  1989cites this paper
• Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.

  1989cites this paper
• Neuropeptide Y and blood pressure in haemodialysis patients.

  1989cites this paper
• Neuropeptide Y- and somatostatin-like immunoreactivities in ganglioneuroma, ganglioneuroblastoma and neuroblastoma.

  1989cites this paper